NantHealth Inc (NASDAQ:NH) COO Ronald Allen Louks sold 6,475 shares of the firm’s stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $3.02, for a total transaction of $19,554.50. Following the completion of the transaction, the chief operating officer now owns 89,690 shares in the company, valued at $270,863.80. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Ronald Allen Louks also recently made the following trade(s):
- On Monday, January 8th, Ronald Allen Louks sold 6,175 shares of NantHealth stock. The stock was sold at an average price of $3.52, for a total transaction of $21,736.00.
- On Wednesday, December 6th, Ronald Allen Louks sold 5,245 shares of NantHealth stock. The stock was sold at an average price of $3.03, for a total transaction of $15,892.35.
Shares of NantHealth Inc (NH) opened at $3.15 on Thursday. The firm has a market cap of $341.24 and a PE ratio of -2.16. NantHealth Inc has a 52-week low of $2.60 and a 52-week high of $8.16. The company has a debt-to-equity ratio of 0.93, a current ratio of 2.38 and a quick ratio of 2.36.
A number of research analysts have recently issued reports on NH shares. Zacks Investment Research downgraded shares of NantHealth from a “buy” rating to a “hold” rating in a research report on Wednesday, October 25th. BidaskClub downgraded shares of NantHealth from a “sell” rating to a “strong sell” rating in a research report on Wednesday, December 6th. Finally, Canaccord Genuity cut their price objective on shares of NantHealth from $6.00 to $5.00 and set a “buy” rating on the stock in a research report on Friday, November 17th. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. NantHealth presently has a consensus rating of “Buy” and a consensus price target of $8.05.
Large investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. increased its stake in NantHealth by 91.5% during the 2nd quarter. Goldman Sachs Group Inc. now owns 169,603 shares of the company’s stock valued at $717,000 after buying an additional 81,024 shares during the period. GSA Capital Partners LLP increased its stake in NantHealth by 154.7% during the 3rd quarter. GSA Capital Partners LLP now owns 72,600 shares of the company’s stock valued at $299,000 after buying an additional 44,100 shares during the period. National Planning Corp increased its stake in NantHealth by 21.1% during the 3rd quarter. National Planning Corp now owns 138,700 shares of the company’s stock valued at $656,000 after buying an additional 24,200 shares during the period. TIAA CREF Investment Management LLC increased its stake in NantHealth by 136.9% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 47,848 shares of the company’s stock valued at $202,000 after buying an additional 27,648 shares during the period. Finally, Schwab Charles Investment Management Inc. acquired a new position in NantHealth during the 3rd quarter valued at about $180,000. Hedge funds and other institutional investors own 7.12% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Insider Selling: NantHealth Inc (NH) COO Sells 6,475 Shares of Stock” was published by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at https://www.americanbankingnews.com/2018/02/08/insider-selling-nanthealth-inc-nh-coo-sells-6475-shares-of-stock.html.
NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.
Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.